[Tumor biochemistry as basis for advances in tumor chemotherapy].
Oncogenes, onc-gene products and the concept of autonomous self-stimulation of tumor growth by autocrine production of growth factors are discussed with regard to the development of new antitumor agents. The significance of the plasma membrane as an attractive target in tumor chemotherapy is emphasized. Membrane bound enzymes and related reactions which are involved in growth factor dependent regulation of cell proliferation offer new targets for antitumor chemotherapy. Examples demonstrating the antiproliferative effects of phospholipase-C and calmodulin inhibitors are presented. A synergistic effect of these drugs with alkylating agents is observed. Studies devoted to the improvement of alkylating antitumor agents have also led to the plasma-membrane as a particularly suited target. The same may be true for other antitumor agents like anthracyclines and platinum complexes for which evidence exists implicating the involvement of cellular membranes in the mechanism of cytotoxic action.
D000477:Alkylating Agents / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002147:Calmodulin / Q000037:antagonists & inhibitors; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002462:Cell Membrane / Q000201:enzymology / Q000378:metabolism; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009857:Oncogenes / Q000187:drug effects; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D010738:Type C Phospholipases / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D002147:Calmodulin; D004273:DNA, Neoplasm; D010982:Platelet-Derived Growth Factor; D004815:Epidermal Growth Factor; D010738:Type C Phospholipases
Tumorbiochemie als Basis für den Fortschritt der Tumorchemotherapie.